Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting
September 30, 2021 11:49 ET
|
Apellis Pharmaceuticals, Inc.
Results further support the efficacy and safety profile of pegcetacoplan, an investigational, targeted C3 therapy, with monthly and every-other-month treatment Pegcetacoplan has the potential to...
Apellis Pharmaceuticals to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 20, 2021 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
September 09, 2021 16:05 ET
|
Apellis Pharmaceuticals, Inc.
OAKS met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of 22% (p=0.0003) and 16% (p=0.0052),...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 07, 2021 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller / Chief Accounting Officer
September 03, 2021 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results
August 09, 2021 16:01 ET
|
Apellis Pharmaceuticals, Inc.
Received approval for EMPAVELI™ (pegcetacoplan) – the first targeted C3 therapy – from U.S. Food and Drug Administration (FDA) for treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 06, 2021 16:05 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
Apellis Pharmaceuticals to Host Conference Call on August 9, 2021 to Discuss Second Quarter 2021 Financial Results
July 29, 2021 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the...
Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
July 26, 2021 07:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of...
Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
July 07, 2021 22:06 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has...